Pyxis Oncology
PYXS
47 hedge funds and large institutions have $41.5M invested in Pyxis Oncology in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
57% more capital invested
Capital invested by funds: $26.5M → $41.5M (+$15M)
52% more funds holding
Funds holding: 31 → 47 (+16)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28.3% less ownership
Funds ownership: 56.3% → 28% (-28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$503K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$289K |
| 3 |
HIS
Harvest Investment Services
Oakbrook Terrace,
Illinois
|
+$182K |
| 4 |
Jane Street
New York
|
+$151K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$145K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.07M |
| 3 |
NM
Newtyn Management
New York
|
-$2.01M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.98M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.66M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACP
51
Acuta Capital Partners
Redwood City,
California
| – | -$897K | -669,158 | Closed |
|
52
Citigroup
New York
| – | -$479K | -357,537 | Closed |
|
|
MAM
53
Marquette Asset Management
Minneapolis,
Minnesota
| – | -$78.9K | -58,862 | Closed |
|
54
Two Sigma Investments
New York
| – | -$47.5K | -35,477 | Closed |
|
55
Millennium Management
New York
| – | -$42K | -31,334 | Closed |
|
PYXS Hedge Fund Activity: Q1 2023 in Review
47 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2023, worth a combined $41.5M — up 57% from $26.5M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PYXS positions and 8 closed out — a net gain of 16 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $503K. The largest seller was BVF Inc, exiting entirely with an estimated $3.94M sold.
- 47 institutional investors held Pyxis Oncology (PYXS) as of Q1 2023, up from 31 in Q4 2022.
- Funds reported $41.5M of Pyxis Oncology stock for Q1 2023, up 57% quarter-over-quarter.
- 24 funds opened new Pyxis Oncology positions in Q1 2023 and 8 closed out, a net change of +16 holders.
- The largest Pyxis Oncology buyer in Q1 2023 was Point72 Asset Management, an estimated $503K added.
- The largest Pyxis Oncology seller in Q1 2023 was BVF Inc, an estimated $3.94M sold.
Based on aggregated 13F filings for Q1 2023.